Matthew Korenberg
2021
In 2021, Matthew Korenberg earned a total compensation of $6.7M as Executive Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 116% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $248,649 |
|---|---|
| Option Awards | $1,082,118 |
| Salary | $497,297 |
| Stock Awards | $4,890,114 |
| Other | $7,300 |
| Total | $6,725,479 |
Korenberg received $4.9M in stock awards, accounting for 73% of the total pay in 2021.
Korenberg also received $248.6K in non-equity incentive plan, $1.1M in option awards, $497.3K in salary and $7.3K in other compensation.
Rankings
In 2021, Matthew Korenberg's compensation ranked 1,844th out of 12,412 executives tracked by ExecPay. In other words, Korenberg earned more than 85.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,844 out of 12,412 | 85th |
Division Manufacturing | 685 out of 5,498 | 88th |
Major group Chemicals And Allied Products | 257 out of 2,374 | 89th |
Industry group Drugs | 218 out of 2,095 | 90th |
Industry Pharmaceutical Preparations | 148 out of 1,542 | 90th |
Source: SEC filing on April 22, 2022.
Korenberg's colleagues
We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2021.